JP2016515800A - 肺癌の予後および治療選択のための遺伝子サイン - Google Patents

肺癌の予後および治療選択のための遺伝子サイン Download PDF

Info

Publication number
JP2016515800A
JP2016515800A JP2015558997A JP2015558997A JP2016515800A JP 2016515800 A JP2016515800 A JP 2016515800A JP 2015558997 A JP2015558997 A JP 2015558997A JP 2015558997 A JP2015558997 A JP 2015558997A JP 2016515800 A JP2016515800 A JP 2016515800A
Authority
JP
Japan
Prior art keywords
types
genes
test
expression
ccg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015558997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515800A5 (enExample
Inventor
スザンヌ ワグナー
スザンヌ ワグナー
スティーブン ストーン
スティーブン ストーン
アレクサンダー グティン
アレクサンダー グティン
ジュリア リード
ジュリア リード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016515800A publication Critical patent/JP2016515800A/ja
Publication of JP2016515800A5 publication Critical patent/JP2016515800A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015558997A 2013-02-21 2014-02-21 肺癌の予後および治療選択のための遺伝子サイン Pending JP2016515800A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361767490P 2013-02-21 2013-02-21
US61/767,490 2013-02-21
US201361860470P 2013-07-31 2013-07-31
US61/860,470 2013-07-31
US201361894733P 2013-10-23 2013-10-23
US61/894,733 2013-10-23
PCT/US2014/017706 WO2014130825A1 (en) 2013-02-21 2014-02-21 Gene signatures for lung cancer prognosis and therapy selection

Publications (2)

Publication Number Publication Date
JP2016515800A true JP2016515800A (ja) 2016-06-02
JP2016515800A5 JP2016515800A5 (enExample) 2017-01-26

Family

ID=51391852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015558997A Pending JP2016515800A (ja) 2013-02-21 2014-02-21 肺癌の予後および治療選択のための遺伝子サイン

Country Status (5)

Country Link
US (1) US20140315935A1 (enExample)
EP (1) EP2958999A4 (enExample)
JP (1) JP2016515800A (enExample)
CA (1) CA2901761A1 (enExample)
WO (1) WO2014130825A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021536434A (ja) * 2018-08-20 2021-12-27 トラスティーズ オブ ボストン ユニバーシティ 気管支前悪性病変の重症度および進行に関する方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE212013000295U1 (de) 2013-05-06 2016-02-02 Hitachi Chemical Co. America, Ltd. Vorrichtungen zum Einfangen von Zielmolekülen
JP6730983B2 (ja) * 2014-09-19 2020-07-29 ザ プロボスト，フェローズ，ファウンデーション スカラーズ，アンド ジ アザー メンバーズ オブ ボード，オブ ザ カレッジ オブ ザ ホーリー アンド アンディブ．トリニティー オブ クイーン エリザベス，ニアー ダブリン 癌の再発リスクを予測する方法
WO2016077537A1 (en) * 2014-11-12 2016-05-19 Hitachi Chemical Co., Ltd. Method and device for diagnosing organ injury
KR101825369B1 (ko) * 2015-06-15 2018-02-06 강원대학교산학협력단 암의 예후 판단용 유전자 바이오 마커 및 이의 용도
WO2017040520A1 (en) 2015-08-31 2017-03-09 Hitachi Chemical Co., Ltd. Molecular methods for assessing urothelial disease
CN111187833A (zh) * 2018-11-14 2020-05-22 上海生物芯片有限公司 Plk1和bub1b基因联合作为肺癌生物标志物的用途
CN118782151B (zh) * 2024-07-24 2025-08-29 西南医科大学附属医院 一种基于“靶点-药物加权积分制”构建脓毒症疾病关键靶点与药物筛选方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012030840A2 (en) * 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
JP2012514474A (ja) * 2009-01-07 2012-06-28 ミリアド・ジェネティックス・インコーポレイテッド がんバイオマーカー

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
CA2845568A1 (en) * 2011-08-19 2013-02-28 Myriad Genetics, Inc. Gene signatures for lung cancer prognosis and therapy selection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012514474A (ja) * 2009-01-07 2012-06-28 ミリアド・ジェネティックス・インコーポレイテッド がんバイオマーカー
WO2012030840A2 (en) * 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021536434A (ja) * 2018-08-20 2021-12-27 トラスティーズ オブ ボストン ユニバーシティ 気管支前悪性病変の重症度および進行に関する方法

Also Published As

Publication number Publication date
EP2958999A4 (en) 2016-10-19
EP2958999A1 (en) 2015-12-30
US20140315935A1 (en) 2014-10-23
WO2014130825A1 (en) 2014-08-28
CA2901761A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
DK2382331T3 (en) CANCER biomarkers
JP6246845B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
US20140170242A1 (en) Gene signatures for lung cancer prognosis and therapy selection
JP2020127416A (ja) ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
ES2938766T3 (es) Firmas génicas para el pronóstico de cáncer
JP2016515800A (ja) 肺癌の予後および治療選択のための遺伝子サイン
MX2013013746A (es) Biomarcadores para cancer de pulmon.
CN109072481B (zh) 早期乳腺癌内分泌治疗后剩余风险的基因特征
EP2531619A2 (en) Hypoxia-related gene signatures for cancer classification
WO2014066796A2 (en) Breast cancer prognosis signatures
US20170137890A1 (en) Cancer prognosis signatures
WO2017193062A1 (en) Gene signatures for renal cancer prognosis
US20140212415A1 (en) Hypoxia-related gene signatures for cancer classification
CA2813257A1 (en) Brca deficiency and methods of use
US20230178177A1 (en) A single patient classifier for t1 high grade bladder cancer
WO2013109690A1 (en) Breast cancer prognosis signatures
US20160281177A1 (en) Gene signatures for renal cancer prognosis
US20140024028A1 (en) Brca deficiency and methods of use
US20220243275A1 (en) Genes and gene signature for diagnosis and treatment of melanoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161209

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171016

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180620